Risk assessment of complications using clot wave form analysis and M2BPGi in patients with cirrhosis

Risk assessment of complications using clot waveform analysis and M2BPGi in patients with cirrhosis: A prospective 2-year follow-up study

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Observational

Source

TCTR

Registry ID

TCTR20200730001

Enrollment

300

Registered

2020-07-30

Start date

2020-07-01

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bleeding complications such as variceal bleeding&#44

Interventions

Patients with cirrhosis who develop bleeding complication during follow&#45

up period.,Patients with cirrhosis who do not develop bleeding complication during follow&#45

up period.

Diagnostic,Diagnostic

Patients with bleeding complication,Patients without bleeding complication

Eligibility

Sex/Gender

All

Age

18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1) Age > 18 years 2) Chronic liver disease from any causes. 3) Advanced liver fibrosis (â‰¥ stage 3) or cirrhosis diagnosed by imaging, histology with/without HCC

Exclusion criteria

Exclusion criteria: 1) Hematologic disease 2) Taking anticoagulants eg. warfarin, enoxaparin, new oral anticoagulants 3) History of endoscopic variceal ligation or sclerosis 4) HIV infection 5) post transplantation

Design outcomes

Primary

Measure	Time frame
Bleeding baseline, 6, 12, 18, 24 months Clot waveform analysis, M2BPGi	—

Secondary

Measure	Time frame
Other complications of liver cirrhosis baseline, 6, 12, 18, 24 months Clot waveform analysis, M2BPGi, Fibroscan	—

Countries

Thailand

Contacts

Public ContactKessarin Thanapirom

Division of Gastroenterology, Department of Medicine, Faculty of Medicine, King Chulalongkorn Memori

tkessarin@hotmail.com66830685211

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026